BRAINSTORM CELL THERAPEUTICS's ticker is BCLI and the CUSIP is 10501E201. A total of 46 filers reported holding BRAINSTORM CELL THERAPEUTICS in Q4 2021. The put-call ratio across all filers is 1.02 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $58,000 | -73.6% | 17,600 | -69.5% | 0.00% | – |
| Q2 2021 | $220,000 | +144.4% | 57,679 | +144.4% | 0.00% | – |
| Q1 2021 | $90,000 | -35.3% | 23,604 | -23.4% | 0.00% | – |
| Q4 2020 | $139,000 | -30.5% | 30,807 | +72.9% | 0.00% | – |
| Q2 2020 | $200,000 | +55.0% | 17,820 | -36.1% | 0.00% | – |
| Q1 2020 | $129,000 | +138.9% | 27,878 | +101.7% | 0.00% | – |
| Q2 2018 | $54,000 | – | 13,820 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SABBY MANAGEMENT, LLC | 242,850 | $923,000 | 0.13% |
| ABNER HERRMAN & BROCK LLC | 241,500 | $918,000 | 0.13% |
| Weaver Consulting Group | 48,881 | $186,000 | 0.10% |
| Tibra Equities Europe Ltd | 87,000 | $331,000 | 0.10% |
| Ikarian Capital, LLC | 293,200 | $1,115,000 | 0.09% |
| GSA CAPITAL PARTNERS LLP | 60,238 | $229,000 | 0.03% |
| Ergoteles LLC | 124,329 | $472,000 | 0.01% |
| CFO4Life Group, LLC | 12,003 | $46,000 | 0.01% |
| HighPoint Advisor Group LLC | 17,033 | $65,000 | 0.01% |
| BOOTHBAY FUND MANAGEMENT, LLC | 32,836 | $125,000 | 0.00% |